
NASDAQHealthcareMedical - Devices
最新データ
$0.735
−$0.0003 · -0.04%
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
前日終値
$0.735
−$0.0003 · -0.04%
日中の時刻はETです。市場データは遅延する場合があります。
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
日中レンジ
現在 $0.735
52週レンジ
現在 $0.735
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
60
適正価値
センチメント
65
強気
リスク
76
高リスク
モメンタム
37
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
日中レンジ
現在 $0.735
52週レンジ
現在 $0.735
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3358.7万 USD | 2805.1万 USD | 2251.9万 USD | 1713.3万 USD | 2323.2万 USD |
| 売上原価 | 2597.9万 USD | 2816万 USD | 2800.4万 USD | 2567.3万 USD | 3097.3万 USD |
| 粗利益 | 760.8万 USD | −10.9万 USD | −548.5万 USD | −854万 USD | −774.1万 USD |
| 研究開発 | 1360.3万 USD | 1459.7万 USD | 1282万 USD | 1286.6万 USD | 978.1万 USD |
| 販売・一般管理 | 3483.6万 USD | 3521.3万 USD | 3825.8万 USD | 4181.3万 USD | 2971万 USD |
| 営業費用 | 5500万 USD | 4981万 USD | 5107.8万 USD | 5467.9万 USD | 3949.1万 USD |
| 受取利息 | 150.9万 USD | 316.4万 USD | 421万 USD | 177.8万 USD | — |
| 支払利息 | 109万 USD | — | — | — | 265万 USD |
| 減価償却費と償却費 | 325.2万 USD | 336.2万 USD | 310.5万 USD | 283.7万 USD | 152.9万 USD |
| 営業利益 | −4739.2万 USD | −4991.9万 USD | −5656.3万 USD | −6321.9万 USD | −4723.2万 USD |
| 純利益 | −4712.3万 USD | −4688.9万 USD | −5246.7万 USD | −6080.6万 USD | −7352.4万 USD |
会社概要が更新されました 2026年11月22日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$1.88
上昇余地(155.78%)この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。